188 related articles for article (PubMed ID: 36620535)
1. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
Cheng Y; Yuan X; Tian Q; Huang X; Chen Y; Pu Y; Long H; Xu M; Ji Y; Xie J; Tan Y; Zhao X; Song H
Front Oncol; 2022; 12():951589. PubMed ID: 36620535
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132.
Cheng Y; Yuan X; Tian Q; Huang X; Chen Y; Pu Y; Long H; Xu M; Ji Y; Xie J; Tan Y; Zhao X; Song H
Front Oncol; 2023; 13():1334938. PubMed ID: 38173839
[TBL] [Abstract][Full Text] [Related]
3. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
[TBL] [Abstract][Full Text] [Related]
4. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
5. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
6. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
7. Anti-Lymphocyte Antigen 6 Complex, Locus E-
Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ
Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and translational pharmacokinetics of a novel THIOMAB™ antibody-antibiotic conjugate against
Deng R; Zhou C; Li D; Cai H; Sukumaran S; Carrasco-Triguero M; Saad O; Nazzal D; Lowe C; Ramanujan S; Kamath AV
MAbs; 2019; 11(6):1162-1174. PubMed ID: 31219754
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
11. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
[TBL] [Abstract][Full Text] [Related]
13. FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
Guo Q; Gao B; Song R; Li W; Xie Q; Lou S; Shen J; Zhao T; Zhang Y; Wu J; Yang T
Mol Cancer Ther; 2024 Jun; ():. PubMed ID: 38940283
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
[TBL] [Abstract][Full Text] [Related]
15. A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.
Zhou DD; Zhai XT; Zhang LW; Xie ZH; Wang Y; Zhen YS; Gao RJ; Miao QF
NPJ Precis Oncol; 2024 Apr; 8(1):94. PubMed ID: 38654141
[TBL] [Abstract][Full Text] [Related]
16. The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Shen M; Liu S; Stoyanova T
Am J Clin Exp Urol; 2021; 9(1):73-87. PubMed ID: 33816696
[TBL] [Abstract][Full Text] [Related]
17. A literature review of the promising future of
Wen Y; Ouyang D; Zou Q; Chen Q; Luo N; He H; Anwar M; Yi W
Ann Transl Med; 2022 Dec; 10(24):1403. PubMed ID: 36660684
[TBL] [Abstract][Full Text] [Related]
18. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
19. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
